Neurogene Inc.’s Post

On Tuesday, July 9, management will participate in the BMO 2024 Genetic Medicines Summit.   To learn more, read our full press release here: https://bit.ly/3L68OBx

Today, we joined the Russell 3000® Index as part of the Russell indexes annual reconstitution.    We are proud of all that we have accomplished that has enabled our addition to this industry benchmarking index.   #RussellRecon   Read our full press release here: https://bit.ly/4eMgh69

Tune in today at 10:40 a.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, participate in a fireside chat at the TD Cowen Genetic Medicines & RNA Summit. A link to the webcast is available here: https://bit.ly/4c8pYKe

We are pleased to announce that the first patient has been dosed in the high-dose cohort of our Phase 1/2 trial of NGN-401 in female pediatric patients with #Rettsyndrome, and that high-dose NGN-401 has been well-tolerated thus far.   In addition, low-dose NGN-401 continues to demonstrate a favorable safety profile. We are joining the Rett syndrome community to discuss these data at the International Rett Syndrome Foundation ASCEND Summit.   Read today’s press release to learn more: https://bit.ly/3XsvGST  

Tune in today at 1:20 p.m. ET to watch our Founder and Chief Executive Officer, Rachel McMinn, present at the Goldman Sachs 45th Annual Global Healthcare Conference. A link to the webcast is available here: https://bit.ly/4bSuYD8

Neurogene had the pleasure of hosting college students from the #NIIMBLeXperience program to learn about the gene therapy manufacturing process and life working at a biotech.   This unique program offers students from traditionally underrepresented populations the opportunity to gain real-world insight into biopharmaceutical industry careers through hands-on activities and direct interactions with industry professionals.   We hope to inspire future generations to pursue careers in biotech and manufacturing!   NIIMBL | The National Institute for Innovation in Manufacturing Biopharmaceuticals To learn more about the program, visit https://lnkd.in/e_g6Q-eW.

We are excited to announce that NGN-401 gene therapy for Rett syndrome was one of only three CBER programs selected for inclusion in the FDA’s START Pilot Program. NGN-401 was selected based on potential for clinical benefits and clinical development program readiness. Through the START Program, we will have opportunities for enhanced communications with the FDA, with the aim to further accelerate the pace of NGN-401’s development. Learn more here: https://bit.ly/3V7DLdd

Today, we reported first quarter 2024 financial results and highlighted recent updates. For full details and results, read today’s press release: https://bit.ly/4bh1Uon